Stratos Wealth Partners LTD. Sells 610 Shares of DexCom, Inc. $DXCM

Stratos Wealth Partners LTD. reduced its holdings in DexCom, Inc. (NASDAQ:DXCM) by 17.8% during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,818 shares of the medical device company’s stock after selling 610 shares during the quarter. Stratos Wealth Partners LTD.’s holdings in DexCom were worth $246,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the business. Horizon Investments LLC increased its stake in DexCom by 2.2% in the 1st quarter. Horizon Investments LLC now owns 5,608 shares of the medical device company’s stock worth $383,000 after acquiring an additional 123 shares during the last quarter. Wedbush Securities Inc. increased its stake in DexCom by 1.2% in the 1st quarter. Wedbush Securities Inc. now owns 13,168 shares of the medical device company’s stock worth $899,000 after acquiring an additional 157 shares during the last quarter. Argonautica Private Wealth Management Inc. increased its stake in DexCom by 3.2% in the 1st quarter. Argonautica Private Wealth Management Inc. now owns 5,958 shares of the medical device company’s stock worth $407,000 after acquiring an additional 182 shares during the last quarter. Meiji Yasuda Asset Management Co Ltd. increased its stake in DexCom by 3.2% in the 1st quarter. Meiji Yasuda Asset Management Co Ltd. now owns 6,019 shares of the medical device company’s stock worth $411,000 after acquiring an additional 187 shares during the last quarter. Finally, Integrated Wealth Concepts LLC increased its stake in DexCom by 6.3% in the 1st quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock worth $227,000 after acquiring an additional 196 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. Argus assumed coverage on DexCom in a research report on Thursday, August 21st. They set a “buy” rating and a $100.00 price objective on the stock. Morgan Stanley increased their price objective on DexCom from $82.00 to $89.00 and gave the company an “equal weight” rating in a research report on Tuesday, July 15th. Truist Financial reduced their price objective on DexCom from $102.00 to $94.00 and set a “buy” rating on the stock in a research report on Wednesday, October 15th. Robert W. Baird reduced their price objective on DexCom from $112.00 to $90.00 and set an “outperform” rating on the stock in a research report on Friday, September 26th. Finally, Mizuho increased their price objective on DexCom from $95.00 to $100.00 and gave the company an “outperform” rating in a research report on Wednesday, July 16th. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $97.19.

DexCom Trading Down 1.0%

NASDAQ DXCM opened at $70.33 on Friday. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $93.25. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.35 and a current ratio of 1.52. The stock has a 50 day simple moving average of $72.37 and a two-hundred day simple moving average of $77.90. The stock has a market cap of $27.58 billion, a P/E ratio of 48.84, a price-to-earnings-growth ratio of 1.48 and a beta of 1.47.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, topping the consensus estimate of $0.45 by $0.03. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The business had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.13 billion. During the same quarter last year, the business posted $0.43 EPS. The business’s revenue was up 15.2% on a year-over-year basis. DexCom has set its FY 2025 guidance at EPS. On average, analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current year.

Insiders Place Their Bets

In other DexCom news, Director Kyle Malady sold 667 shares of the stock in a transaction that occurred on Friday, September 5th. The stock was sold at an average price of $80.86, for a total value of $53,933.62. Following the completion of the sale, the director owned 22,667 shares in the company, valued at approximately $1,832,853.62. This trade represents a 2.86% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Sadie Stern sold 1,466 shares of the stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $80.00, for a total value of $117,280.00. Following the completion of the sale, the executive vice president owned 105,223 shares of the company’s stock, valued at approximately $8,417,840. This trade represents a 1.37% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 6,849 shares of company stock worth $564,733. Corporate insiders own 0.32% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.